(Q38063819)

28 August 2017

1 reference

title

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine (English)

1 reference

28 August 2017

Masanori Noguchi

1

1 reference

28 August 2017

Tetsuro Sasada

series ordinal

2

1 reference

28 August 2017

Kyogo Itoh

series ordinal

3

1 reference

28 August 2017

30 November 2012

1 reference

Cancer Immunology, Immunotherapy

28 August 2017

1 reference

28 August 2017

62

1 reference

28 August 2017

919-929

1 reference

28 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-012-1379-1

28 August 2017

0 references

cites work

Therapeutic cancer vaccines: current status and moving forward

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1379-1

10.1007/S00262-012-1379-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference